T-Vec: Plus Pembro in Advanced Melanoma Patients the MASTERKEY-115 Phase 2 Trial Brian Gastman MD - Synopsis below extracted from the video transcript.
The Masterkey-115 clinical trial, led by Dr. Brian Gastman, investigated the efficacy of combining T-Vec and pembrolizumab in treating patients with advanced melanoma. In the trial, patients were randomly assigned to either the combination therapy group or the pembrolizumab monotherapy group.
T-Vec is an oncolytic virus therapy that works by infecting and destroying cancer cells while also stimulating the immune system to target the tumor. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
The results of the trial showed that the combination therapy group had a higher overall response rate compared to the monotherapy group. The combination group also had a longer progression-free survival and overall survival.
The trial demonstrated that the combination therapy was generally well-tolerated by patients, with most adverse events being mild or moderate in severity. The most common adverse events included fatigue, fever, and chills.
The study highlights the potential of combining different types of cancer therapies to enhance treatment efficacy. The combination of T-Vec and pembrolizumab targets the cancer cells in multiple ways, leading to better outcomes for patients with advanced melanoma.
In conclusion, the Masterkey-115 trial led by Dr. Gastman provides promising results for the use of T-Vec and pembrolizumab combination therapy in treating advanced melanoma. This combination therapy may offer a new treatment option for patients with this aggressive form of skin cancer. However, further studies are needed to validate these findings and determine the long-term safety and efficacy of the treatment.
